[go: up one dir, main page]

AU2002313559A1 - Genes - Google Patents

Genes

Info

Publication number
AU2002313559A1
AU2002313559A1 AU2002313559A AU2002313559A AU2002313559A1 AU 2002313559 A1 AU2002313559 A1 AU 2002313559A1 AU 2002313559 A AU2002313559 A AU 2002313559A AU 2002313559 A AU2002313559 A AU 2002313559A AU 2002313559 A1 AU2002313559 A1 AU 2002313559A1
Authority
AU
Australia
Prior art keywords
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002313559A
Inventor
Robert Alan Harris
Susan Mary Kingsman
Christopher Robert Mundy
Stuart Naylor
Neil Raymond Ward
Jonathan White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford Biomedica UK Ltd
Original Assignee
Oxford Biomedica UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0120558A external-priority patent/GB0120558D0/en
Priority claimed from GB0124037A external-priority patent/GB0124037D0/en
Application filed by Oxford Biomedica UK Ltd filed Critical Oxford Biomedica UK Ltd
Publication of AU2002313559A1 publication Critical patent/AU2002313559A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2002313559A 2001-08-23 2002-08-23 Genes Abandoned AU2002313559A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0120558A GB0120558D0 (en) 2001-08-23 2001-08-23 Genes
GB0120558.2 2001-08-23
GB0124037.3 2001-10-05
GB0124037A GB0124037D0 (en) 2001-10-05 2001-10-05 Genes
PCT/GB2002/003892 WO2003018621A2 (en) 2001-08-23 2002-08-23 Genes

Publications (1)

Publication Number Publication Date
AU2002313559A1 true AU2002313559A1 (en) 2003-03-10

Family

ID=26246469

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002313559A Abandoned AU2002313559A1 (en) 2001-08-23 2002-08-23 Genes

Country Status (2)

Country Link
AU (1) AU2002313559A1 (en)
WO (1) WO2003018621A2 (en)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2143438B1 (en) 2001-09-18 2011-07-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumors
WO2003070936A1 (en) * 2002-02-20 2003-08-28 Yamanouchi Pharmaceutical Co., Ltd. Novel polypeptide
NZ536205A (en) * 2002-04-30 2008-04-30 Stratatech Corp Keratinocytes expressing exogenous angiogenic growth factors
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
EP1631678A1 (en) * 2003-05-19 2006-03-08 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kell blood group antigen (kel)
PT2489364E (en) 2003-11-06 2015-04-16 Seattle Genetics Inc Monomethylvaline compounds conjugated to antibodies
US20050209178A1 (en) * 2004-03-16 2005-09-22 Stefan Pulst Methods and compositions for the treatment of obesity
DE102004023187A1 (en) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identification of surface-associated antigens for tumor diagnosis and therapy
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
NZ553500A (en) 2004-09-23 2009-11-27 Genentech Inc Genentech Inc Cysteine engineered antibodies and conjugates withCysteine engineered antibodies and conjugates with a free cysteine amino acid in the heavy chain a free cysteine amino acid in the heavy chain
WO2007028631A1 (en) * 2005-09-09 2007-03-15 H. Lundbeck A/S Genetic risk factor for neurodevelopmental disorders and their complications
GB0705626D0 (en) * 2007-03-23 2007-05-02 Royal Veterinary College Method for enhancing sperm survival
CA2809819A1 (en) 2009-09-09 2011-03-17 Centrose, Llc Extracellular targeted drug conjugates
MA34277B1 (en) 2010-04-15 2013-06-01 Spirogen Developments Sarl PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF
US9000130B2 (en) 2010-06-08 2015-04-07 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN103313990B (en) 2010-11-17 2016-07-20 基因泰克公司 Alanyl maytansinol antibody coupling matter
ES2567276T3 (en) 2011-05-12 2016-04-21 Genentech, Inc. LC-MS / MS method of monitoring multiple reactions to detect therapeutic antibodies in animal samples using frame-changing peptides
DK2750713T3 (en) 2011-10-14 2015-12-21 Medimmune Ltd PYRROLOBENZODIAZEPINS AND CONJUGATES THEREOF
WO2013130093A1 (en) 2012-03-02 2013-09-06 Genentech, Inc. Biomarkers for treatment with anti-tubulin chemotherapeutic compounds
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2014057114A1 (en) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Pyrrolobenzodiazepine-anti-psma antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
KR101995621B1 (en) 2012-10-12 2019-07-03 에이디씨 테라퓨틱스 에스에이 Pyrrolobenzodiazepine-anti-cd22 antibody conjugates
JP6270859B2 (en) 2012-10-12 2018-01-31 エイディーシー・セラピューティクス・エス・アー・エール・エルＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａｒｌ Pyrrolobenzodiazepine-antibody conjugate
JP5993093B2 (en) 2012-10-12 2016-09-14 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ Pyrrolobenzodiazepines and their complexes
EP2906296B1 (en) 2012-10-12 2018-03-21 ADC Therapeutics SA Pyrrolobenzodiazepine-antibody conjugates
HK1216176A1 (en) 2012-12-21 2016-10-21 Medlmmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
AU2013366493B2 (en) 2012-12-21 2017-08-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014159981A2 (en) 2013-03-13 2014-10-02 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
AU2014229529B2 (en) 2013-03-13 2018-02-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10442836B2 (en) 2013-08-12 2019-10-15 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
BR112016013258A2 (en) 2013-12-16 2018-01-16 Genentech Inc antibody-drug conjugate, pharmaceutical composition, method for treating cancer and kit
BR112016013861A2 (en) 2013-12-16 2017-10-10 Genentech Inc drug and antibody conjugates, compounds, treatment method and pharmaceutical composition
WO2015095223A2 (en) 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
CN106687141A (en) 2014-09-10 2017-05-17 麦迪穆有限责任公司 Pyrrolobenzodiazepines and conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
MX2017003123A (en) 2014-09-12 2017-05-12 Genentech Inc Cysteine engineered antibodies and conjugates.
WO2016040825A1 (en) 2014-09-12 2016-03-17 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
SG11201702079UA (en) 2014-09-17 2017-04-27 Genentech Inc Pyrrolobenzodiazepines and antibody disulfide conjugates thereof
BR112017011111A2 (en) 2014-11-25 2017-12-26 Adc Therapeutics Sa pyrrolobenzodiazepine-antibody conjugates
EP3226909A1 (en) 2014-12-03 2017-10-11 Genentech, Inc. Quaternary amine compounds and antibody-drug conjugates thereof
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
MA43345A (en) 2015-10-02 2018-08-08 Hoffmann La Roche PYRROLOBENZODIAZEPINE ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
MA43354A (en) 2015-10-16 2018-08-22 Genentech Inc CONJUGATE DRUG CONJUGATES WITH CLOUDY DISULPHIDE
MA45326A (en) 2015-10-20 2018-08-29 Genentech Inc CALICHEAMICIN-ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN121431692A (en) 2016-03-25 2026-01-30 豪夫迈·罗氏有限公司 Multiplex total antibodies and antibody conjugated drug quantification assays
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
JP2019522633A (en) 2016-05-20 2019-08-15 ジェネンテック， インコーポレイテッド PROTAC antibody conjugates and methods of use
JP7022080B2 (en) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド Biochemical analytical methods for the characterization of site-specific antibody-drug conjugates
EP3464280B1 (en) 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
JP7093767B2 (en) 2016-08-11 2022-06-30 ジェネンテック， インコーポレイテッド Pyrrolobenzodiazepine prodrug and its antibody conjugate
JP7050770B2 (en) 2016-10-05 2022-04-08 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Method for preparing antibody drug conjugate
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
HUE054689T2 (en) 2017-02-08 2021-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine antibody conjugates
SI3612537T1 (en) 2017-04-18 2022-10-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
EP3612234B1 (en) 2017-04-20 2024-03-13 ADC Therapeutics SA Combination therapy with an anti-axl antibody-drug conjugate
CA3064804A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
SG11202000358YA (en) 2017-08-18 2020-02-27 Medimmune Ltd Pyrrolobenzodiazepine conjugates
IL273387B2 (en) 2017-09-20 2023-10-01 Ph Pharma Co Ltd Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
JP2022513198A (en) 2018-12-10 2022-02-07 ジェネンテック， インコーポレイテッド Photocrosslinkable peptide for site-specific conjugation to Fc-containing proteins
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
MX2021010477A (en) 2019-03-15 2021-10-01 Medimmune Ltd Azetidobenzodiazepine dimers and conjugates comprising them for use in the treatment of cancer.
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2024138128A2 (en) 2022-12-23 2024-06-27 Genentech, Inc. Cereblon degrader conjugates, and uses thereof
CN121263210A (en) 2023-04-17 2026-01-02 沛科生物公司 Antibodies and antibody-drug conjugates, as well as their usage, synthesis processes, and intermediates
WO2026006689A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Bcl-xl degrader antibody conjugates and uses thereof
WO2026006688A2 (en) 2024-06-28 2026-01-02 Firefly Bio, Inc. Degrader antibody conjugates and uses thereof

Also Published As

Publication number Publication date
WO2003018621A8 (en) 2004-02-19
WO2003018621A2 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
AU2002313559A1 (en) Genes
AU2001240103A1 (en) Reproduction-specific genes
AU2001264247A1 (en) GASC1 gene
AU2001285743A1 (en) Adipose-related gene
AU2002226571A1 (en) Biligands
AU2001100406A4 (en) DriverSMS
AU2002308879A1 (en) Stat6-activating genes
AU2002328863A1 (en) Oncosuppressive gene
AU2002210985A1 (en) Pca2501 gene
AU2002257925A1 (en) Numberplates
HK1060579A (en) Oncosuppressive gene
AU2002343924A1 (en) Hepnadc gene
AUPR959901A0 (en) Stress genes
AU2002337325A1 (en) Gene expression
AU2001100522A4 (en) e-Trans
AU2001100532A4 (en) FonePark
AU2001100214A4 (en) Dolly-trolley
AU2001100338A4 (en) Sunglove
AU2002100746A4 (en) Adrail
HK1063063A (en) Improved gene expression
AU2002328518A1 (en) Novel gene nedl-1
AU2002232173A1 (en) Novel gene tcif
AU2002244928A1 (en) Cancer-associated genes
AU2002234752A1 (en) Hypoxia-regulated genes
GB0130796D0 (en) Genes

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase